Kyntra Bio Depreciation & Amortization Growth & History (KYNB)
Kyntra Bio's depreciation and amortization was $748,000 for fiscal 2025.
View full Kyntra Bio company overviewKyntra Bio annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $748,000 | −$1.9M | −72.21% |
| 2024 | 2024-12-31 | $2.7M | −$7.2M | −72.89% |
| 2023 | 2023-12-31 | $9.9M | −$674,000 | −6.36% |
| 2022 | 2022-12-31 | $10.6M | −$4.2M | −28.39% |
| 2021 | 2021-12-31 | $14.8M | −$7.2M | −32.83% |
| 2020 | 2020-12-31 | $22.0M | $593,000 | +2.76% |
| 2019 | 2019-12-31 | $21.5M | $14.9M | +226.94% |
| 2018 | 2018-12-31 | $6.6M | $463,000 | +7.59% |
| 2017 | 2017-12-31 | $6.1M | $59,000 | +0.98% |
| 2016 | 2016-12-31 | $6.0M | $361,000 | +6.36% |
| 2015 | 2015-12-31 | $5.7M | $1.2M | +27.05% |
| 2014 | 2014-12-31 | $4.5M | −$614,000 | −12.08% |
| 2013 | 2013-12-31 | $5.1M | — | — |
Kyntra Bio quarterly depreciation and amortization
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $6,000 | −$215,000 | −97.29% |
| Q1 2026 | 2026-03-31 | $7,000 | −$320,000 | −97.86% |
| Q4 2025 | 2025-12-31 | $8,000 | — | — |
| Q3 2025 | 2025-09-30 | $192,000 | −$547,000 | −74.02% |
| Q2 2025 | 2025-06-30 | $221,000 | −$560,000 | −71.70% |
| Q1 2025 | 2025-03-31 | $327,000 | −$493,000 | −60.12% |
| Q3 2024 | 2024-09-30 | $739,000 | −$1.9M | −71.93% |
| Q2 2024 | 2024-06-30 | $781,000 | −$1.9M | −71.20% |
| Q1 2024 | 2024-03-31 | $820,000 | −$2.1M | −72.34% |
| Q3 2023 | 2023-09-30 | $2.6M | −$46,000 | −1.72% |
| Q2 2023 | 2023-06-30 | $2.7M | $61,000 | +2.30% |
| Q1 2023 | 2023-03-31 | $3.0M | $381,000 | +14.74% |
| Q3 2022 | 2022-09-30 | $2.7M | $88,000 | +3.40% |
| Q2 2022 | 2022-06-30 | $2.7M | −$1.6M | −38.29% |
| Q1 2022 | 2022-03-31 | $2.6M | −$2.8M | −51.60% |
| Q3 2021 | 2021-09-30 | $2.6M | −$3.0M | −53.51% |
| Q2 2021 | 2021-06-30 | $4.3M | −$1.2M | −22.20% |
| Q1 2021 | 2021-03-31 | $5.3M | −$123,000 | −2.25% |
| Q3 2020 | 2020-09-30 | $5.6M | −$199,000 | −3.45% |
| Q2 2020 | 2020-06-30 | $5.5M | $172,000 | +3.21% |
| Q1 2020 | 2020-03-31 | $5.5M | $149,000 | +2.80% |
| Q3 2019 | 2019-09-30 | $5.8M | $4.2M | +258.51% |
| Q2 2019 | 2019-06-30 | $5.3M | $3.8M | +242.07% |
| Q1 2019 | 2019-03-31 | $5.3M | $3.8M | +249.77% |
| Q3 2018 | 2018-09-30 | $1.6M | $100,000 | +6.62% |
| Q2 2018 | 2018-06-30 | $1.6M | $17,000 | +1.10% |
| Q1 2018 | 2018-03-31 | $1.5M | −$6,000 | −0.39% |
| Q3 2017 | 2017-09-30 | $1.5M | −$3,000 | −0.20% |
| Q2 2017 | 2017-06-30 | $1.5M | $42,000 | +2.79% |
| Q1 2017 | 2017-03-31 | $1.5M | $23,000 | +1.53% |
| Q3 2016 | 2016-09-30 | $1.5M | $91,000 | +6.40% |
| Q2 2016 | 2016-06-30 | $1.5M | $97,000 | +6.89% |
| Q1 2016 | 2016-03-31 | $1.5M | $114,000 | +8.21% |
| Q3 2015 | 2015-09-30 | $1.4M | −$65,000 | −4.37% |
| Q2 2015 | 2015-06-30 | $1.4M | $477,000 | +51.24% |
| Q1 2015 | 2015-03-31 | $1.4M | $476,000 | +52.19% |
| Q3 2014 | 2014-09-30 | $1.5M | — | — |
| Q2 2014 | 2014-06-30 | $931,000 | — | — |
| Q1 2014 | 2014-03-31 | $912,000 | — | — |
Kyntra Bio depreciation and amortization trends
Over the last five fiscal years, Kyntra Bio's depreciation and amortization decreased from $22.0M to $748,000, a change of −$21.3M. The latest reported quarter, Q2 2026, shows $6,000.
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Kyntra Bio source filings ↗